Is there a scientific rationale for therapeutic plasma exchange or intravenous immune globulin in the treatment of acute Guillain-Barré syndrome?
Weinstein
R
R
Department of Medicine, St. Elizabeth's Medical Center of Boston, Tufts University School of Medicine, Massachusetts 02135, USA.
D000208:Acute Disease; D000276:Adjuvants, Immunologic / Q000627:therapeutic use; D000917:Antibody Formation; D005732:Gangliosides / Q000276:immunology; D006801:Humans; D007111:Immunity, Cellular; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use*; D010951:Plasma Exchange; D011129:Polyradiculoneuropathy / Q000628:therapy*
D000276:Adjuvants, Immunologic; D005732:Gangliosides; D016756:Immunoglobulins, Intravenous